Anti-nephrin antibody: a potential biomarker of minimal change disease
Clinical Kidney Journal · 04.03.2025 · 18 (3)
DOI: 10.1093/ckj/sfaf012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 20.01.2025. Verfasst von Qiaoling Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Fujian Medical University Union Hospital, Fuzhou, China. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fujian Provincial Health Technology Project.
Abstract (Originalsprache)
Background
Minimal change disease (MCD) is a common pathological type of nephrotic syndrome in children and adults, and the mechanisms remain obscure. The diagnosis of MCD still relies on renal biopsy, lacking effective biological markers. This study explores the diagnostic value of circulating anti-nephrin antibody in MCD patients and evaluates the correlation with disease activity indicators such as proteinuria.
Methods
The study included 108 adult patients with glomerular disease, including 36 with MCD, 16 with primary focal segmental glomerulosclerosis (FSGS), 20 with primary membranous nephropathy (MN), 17 with diabetic nephropathy (DN) and 19 with immunoglobulin A nephropathy (IgAN). Twenty healthy volunteers were included. Circulating anti-nephrin antibody was detected by indirect immunofluorescence method of cell-based assay. The receiver-operating characteristic (ROC) curve was used to evaluate the role of circulating anti-nephrin antibody in the diagnosis of MCD. The correlations between anti-nephrin antibody and clinical parameters were analyzed.
Results
The prevalence of circulating anti-nephrin antibody was 19.44% (7 of 36) in MCD and 26.92% (7 of 26) in MCD patients with nephrotic proteinuria, which was higher than in FSGS, PMN, DN, IgAN and healthy volunteers. The ROC curve showed that the sensitivity of anti-nephrin antibody used in the diagnosis of MCD was 19.4% and the specificity was 97.8%. The MCD patients with positive anti-nephrin antibody had heavier proteinuria and higher serum lipid levels, while having lower serum albumin and blood IgG levels. Anti-nephrin antibody might turn to negative when the MCD patient had a response to therapy.
Conclusions
Circulating anti-nephrin antibody may be a potential biomarker of MCD and may play a role in the MCD diagnosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, Fujian Medical University Union Hospital, Fuzhou, China.
- Fujian Institute of Clinical Immunology, Fuzhou, China.
Förderung
- Fujian Provincial Health Technology Project
Zitieren
APA
Chen, Q., Chen, S., Ye, Q., Lin, W., Liao, Y., Xiong, Y., Xu, J., Gao, R., Li, B., Liu, L., & Wei, L. (2025). Anti-nephrin antibody: a potential biomarker of minimal change disease. Clinical Kidney Journal, 18(3). https://doi.org/10.1093/ckj/sfaf012
Vancouver
Chen Q, Chen S, Ye Q, Lin W, Liao Y, Xiong Y, et al. Anti-nephrin antibody: a potential biomarker of minimal change disease. Clinical Kidney Journal. 2025;18(3). doi:10.1093/ckj/sfaf012
BibTeX
@article{Chen2025,
author = {Chen, Qiaoling and Chen, Sihui and Ye, Qiuping and Lin, Wanjun and Liao, Yonggen and Xiong, Yunfeng and Xu, Jiaming and Gao, Ruiyu and Li, Binbin and Liu, Lifang and Wei, Lixin},
title = {Anti-nephrin antibody: a potential biomarker of minimal change disease},
journal = {Clinical Kidney Journal},
year = {2025},
volume = {18},
number = {3},
doi = {10.1093/ckj/sfaf012}
}
EUVIMED